AMTAGVI

This brand name is authorized in United States.

Active ingredients

The drug AMTAGVI contains one active pharmaceutical ingredient (API):

1	Lifileucel UNII R0835E18NH - LIFILEUCEL
	Lifileucel is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The specific mechanism of action of lifileucel is unknown.
	Read more about Lifileucel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AMTAGVI Suspension for intravenous infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XL11		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	73776-001